BRAF anticorps (N-Term)

N° du produit ABIN7860825

L’anticorps anti-BRAF Monoclonal Souris est utilisé pour la détection de BRAF dans des échantillons de Humain. Il a été validé pour WB et ELISA.

Aperçu rapide pour BRAF anticorps (N-Term) (ABIN7860825)

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BRAF est non-conjugé

Application: Western Blotting (WB), ELISA

Clone: V600E-1321

Détail du produit anti-BRAF anticorps

Épitope: AA 596-606, N-Term

Fonction: BRAF (V600E Mutant Specific) (Prognostic Marker) Antibody

Specificité: TheÇ 79oΩBRAFÇ 79oΩgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. TheÇ 79oΩBRAFÇ 79oΩV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas.Ç 79oΩFurthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia,Ç 79oΩ54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytosesÇ 79oΩand 60 % of pleomorphic xanthoastrocytomas.Ç 79oΩ

Purification: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

Immunogène: An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Prepared in 10  mM PBS

Agent conservateur: Azide free

Stock: -20 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur BRAF

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Autre désignation: BRAF

Sujet:

FLJ95109, 94 kDa B raf protein, B Raf proto oncogene, serine/threonine kinase, B RAF1, B-Raf proto-oncogene serine/threonine-protein kinase (p94), BRAF 1, BRAF, BRAF1, cRmil, MGC126806, MGC138284, Murine sarcoma viral (v-raf) oncogene homolog B1, NS7, oncogene BRAF1, p94, Proto-oncogene B-Raf, Proto-oncogene c-Rmil, RAFB1, RMIL, Serine/threonine-protein kinase B-raf, v-Raf murine sarcoma viral oncogene homolog B1

A431|Jurkat and HeLa cells. Human melanoma and colon carcinoma, Human Skeletal Muscles

Poids moléculaire: 35kDa (predicted)

ID gène: 673, 550061

UniProt: P15056

Pathways: Signalisation MAPK, Signalisation RTK, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy